Fortress Biotech, Inc. Q3 2025 Earnings Recap

FBIO Q3 2025 November 13, 2025

Journey Medical delivered robust performance in Q3 2025, achieving 21% year-over-year revenue growth, driven primarily by the strong uptake of its new oral treatment, EMROSI.

Earnings Per Share Beat

$0.11 vs $-0.43 est.

+125.6% surprise

Revenue Miss

17631000 vs 21018500 est.

-16.1% surprise

Market Reaction

1-Day -4.96%

5-Day +1.91%

30-Day +10.31%

Key Takeaways

EMROSI contributed $4.9 million, showing a 75% revenue increase compared to Q2, with total prescriptions growing 146%.
Despite a 16% year-over-year decline in revenue for legacy products due to Accutane generic competition, overall product revenues grew by more than 16% year-over-year.
Operating expenses rose only 9%, highlighting effective expense management linked to EMROSI's launch and potential for sustainable EBITDA positivity in Q4.
Over 2,700 unique prescribers have adopted EMROSI, a 50% increase since the last earnings call, indicating strong market acceptance and growth potential.
The company has secured access for EMROSI across over 100 million of the 187 million commercial lives, with further GPO contracting expected.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit FBIO on AllInvestView.